BACKGROUND: Anemia is a marker of worsened clinical outcome in patients with heart failure from left ventricular dysfunction. Pulmonary hypertension often results in right ventricular dysfunction. Accordingly we sought to examine the association of hemoglobin levels and long-term all-cause mortality in a cohort of patients with pulmonary hypertension. METHODS: Baseline demographic information, clinical characteristics and fasting blood work were obtained in a cohort of 145 patients with pulmonary hypertension referred for pulmonary vasodilator testing. Data was retrospectively analyzed with Cox-proportional hazards analysis. RESULTS: Baseline characteristics of the cohort included age (mean±SD) 55.8±14.6 years, 75% women, 50% with idiopathic pulmonary hypertension, mean pulmonary artery pressure 46.1±14.2 mm Hg and arterial O(2) saturation 91±6 %. The most commonly utilized pulmonary hypertension specific therapeutic agents in descending order of frequency were epoprostenol (27%), sildenafil (21%), bosentan (17%), and treprostinil (6%). Over a median follow-up of 2.1 years, there were 39 deaths (26.9%). Patients who died had significantly lower hemoglobin levels than those survived (12.2±2.3 vs. 13.7±2.0, p<0.001). After adjustment for known predictors of death and pulmonary hypertension etiology, anemic patients were 3.3 times more likely to die than non-anemic patients (95% CI [1.43-7.51], p=0.005). CONCLUSIONS: Hemoglobin levels closely parallel survival in pulmonary hypertension. Modification of anemia in this disorder could alter the clinical course and calls for further research in this area.
BACKGROUND:Anemia is a marker of worsened clinical outcome in patients with heart failure from left ventricular dysfunction. Pulmonary hypertension often results in right ventricular dysfunction. Accordingly we sought to examine the association of hemoglobin levels and long-term all-cause mortality in a cohort of patients with pulmonary hypertension. METHODS: Baseline demographic information, clinical characteristics and fasting blood work were obtained in a cohort of 145 patients with pulmonary hypertension referred for pulmonary vasodilator testing. Data was retrospectively analyzed with Cox-proportional hazards analysis. RESULTS: Baseline characteristics of the cohort included age (mean±SD) 55.8±14.6 years, 75% women, 50% with idiopathic pulmonary hypertension, mean pulmonary artery pressure 46.1±14.2 mm Hg and arterial O(2) saturation 91±6 %. The most commonly utilized pulmonary hypertension specific therapeutic agents in descending order of frequency were epoprostenol (27%), sildenafil (21%), bosentan (17%), and treprostinil (6%). Over a median follow-up of 2.1 years, there were 39 deaths (26.9%). Patients who died had significantly lower hemoglobin levels than those survived (12.2±2.3 vs. 13.7±2.0, p<0.001). After adjustment for known predictors of death and pulmonary hypertension etiology, anemicpatients were 3.3 times more likely to die than non-anemicpatients (95% CI [1.43-7.51], p=0.005). CONCLUSIONS: Hemoglobin levels closely parallel survival in pulmonary hypertension. Modification of anemia in this disorder could alter the clinical course and calls for further research in this area.
Authors: Ilka Decker; Sudakshina Ghosh; Suzy A Comhair; Samar Farha; Wai Hong Wilson Tang; Margaret Park; Sihe Wang; Alan E Lichtin; Serpil C Erzurum Journal: Clin Transl Sci Date: 2011-08 Impact factor: 4.689
Authors: Samar Farha; Kewal Asosingh; Weiling Xu; Jacqueline Sharp; Deepa George; Suzy Comhair; Margaret Park; W H Wilson Tang; James E Loyd; Karl Theil; Raymond Tubbs; Eric Hsi; Alan Lichtin; Serpil C Erzurum Journal: Blood Date: 2011-01-21 Impact factor: 22.113
Authors: Jill M Cholette; Ariane Willems; Stacey L Valentine; Scot T Bateman; Steven M Schwartz Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624
Authors: Gerrina Ruiter; Emmy Manders; Chris M Happé; Ingrid Schalij; Herman Groepenhoff; Luke S Howard; Martin R Wilkins; Harm J Bogaard; Nico Westerhof; Willem J van der Laarse; Frances S de Man; Anton Vonk-Noordegraaf Journal: Pulm Circ Date: 2015-09 Impact factor: 3.017
Authors: Jacqueline Sharp; Samar Farha; Margaret M Park; Suzy A Comhair; Erika L Lundgrin; W H Wilson Tang; Robert D Bongard; Marilyn P Merker; Serpil C Erzurum Journal: Redox Biol Date: 2014-07-31 Impact factor: 11.799